Scientific Validation for Glutathione
The efficacy of glutathione has been established by the world's leading scientists and researchers as the master anti-oxidant. Many business analysts and healthcare professionals believe this breakthrough in medical science will lead to glutathione becoming as well known as Penicillin, very soon.
If you wish to read any of the abstracts listed below, please click on the appropriate graphic. When you click on a graphic, a new page will open. When you close it again, you will return to this page.
Contact Us with any questions you have, or to receive information on a product proven to raise intercellular glutathione levels.
The following are some references for Parkinson's disease.
ADAMS JD JR, KLAIDMAN LK, ODUNZE IN, SHEN HC, MILLER CA. Alzheimer's and Parkinson's disease. Brain levels of glutathione, glutathione disulfide, and vitamin E. Molecular Chemical Neuropathology 14(3):213-226, 1991
ADAMS JD JR, ODUNZE IN. Oxygen free radical and Parkinson's disease. Free Radical Biol Med 10(2):161-169, 1991
DI MONTE DA, CHAN P, SANDY MS. Glutathione in Parkinson's disease: a link between oxidative stress and mitochondrial damage. Annals of Neurology 32(suppl): SIII-115, 1992
EBADI M, SRINIVASAN SK, BAXI MD. Oxidative stress and antioxidant therapy in Parkinson's disease. Progress in Neurobiology 48(I):1-19, 1996
GABBY M, TAUBER M, PORAT S, SIMANTOV R. Selective role of glutathione in protecting human neuronal cells from dopamine-induced apoptosis. Neuropharmacology 35(5):57-578, 1996
JENNER P. Oxidative damage in neurodegenerative disease. The Lancet 344:796-798, 1994 JENNER P. Oxidative stress in Parkinson's disease and other neurodegenerative disorders. Pathologie Biologie 44(I):57-64, 1996
JENNER P, OLANOW CW. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47(6 suppl3):S161-170, 1996
OWEN AD, SCHAPIRA AHV, JENNER P, MARSDEN CD. Oxidative stress and Parkinson's disease. Annals of the New York Academy of Science 786-217-223, 1996
OFFEN D, ZRV I, STERNIN H, MELAMED E, HOCHMAN A. Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Experimental Biology 141(1):32-39, 1996
PERRY TL, GODIN DV, HANSEN S. Parkinson's disease: a disorder due to nigral glutathione deficiency. Neuroscience Letter 33(3):305-310, 1982
REIDERER P, SOFIC E, RAUSCH WD, SCHMIDT B ET AL. Transition metals, ferritin, glutathione, ascorbic acid in Parkinsonian Brains. Journal of Neurochemistry 52:515-520, 1989
SECHI G, DELEDDA MG, BUA G, SATTA WM, DEIANA GA, PES GM, ROSATI G. Reduced intravenous glutathione in the treatment of early Parkinson's disease. Progress in Neuro-Psychopharmacology & Biological Psychiatry 20(7):1159-70, 1996
SIAN J, DEXTER DT, LEES AJ, DANIEL S, JENNER P, MARSDEN CD. Glutathione-related enzymes in brain in Parkinson's disease. Annals of Neurology 36(3):356-361, 1994
SIAN J, DEXTER DT, LEES AJ, DANIEL S, AGID Y, JAVOY-AGID F, JENNER P, MARSDEN CD. Alterations in glutathion levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Annals of Neurology 36(3): 348-355, 1994
SIMONIAN NA, COYLE JT. Oxidative stress in neurodegenerative diseases. Annual Review of Pharmacology & Toxicology 36:83-106, 1996
SPENCER JPE, JENNER P, HALLIWELL B. Superoxide-dependent depletion of reduced glutathione by L-Dopa and dopamine. Relevance to Parkinson's disease. Neuroreport 6(11):1480-84, 1995
ZHANG F, DRYHURST G. Effects of L-cysteine on the oxidation chemistry of dopamine: new reaction pathways of potential relevance to idiopathic Parkinson's disease. Journal of Medical Chemistry 37(8):1084-98, 1994
Click on the references link, this will take you to a page of further resources.
To top of page